Industry News

23 April 2015

Lupin introduce Zaxine in Canada for liver disease treatment

Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.
- Read more about AstraZeneca's selumetinib get US FDA orphan drug status for uveal melanoma treatment
AstraZeneca, a global, innovation-driven biopharmaceutical business, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.
- Read more about Comfortably Numb Device arrest Pain of Drug Injections
A team of three engineering students from Rice University, Houston, United States, created the device to ease the pain of an injection. A new drug injector called "Comfortably Numb" is a cooling device. It numbs the skin prior to getting a shot. It works like an ice pack, which produces a rapid chemical reaction that cools and numbs patients' skin in seconds. The device consists of a small 3D-printed cylinder with a metal plate at one end. It contain ammonium nitrate and water in separate compartments.
- Read more about Aeterna Zentaris plans to conduct phase 3 study of Macrilen in AGHD
Aeterna Zentaris Inc., a specialty biopharmaceutical company, is planning to conduct a new, confirmatory phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (AGHD), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarisation.
- Read more about Sagent Pharma Notify the Launch of Vancomycin Hydrochloride for Injection
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company has launched Vancomycin hydrochloride for injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation.
- Read more about Exelixis’ cabozantinib received Fast Track designation by US FDA for RCC treatment
The US Food & Drug Administration (FDA) has granted Fast Track designation to Exelixis, Inc's cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC). Cabozantinib is the Exelixis' lead compound . Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.
- Read more about Dr. Reddy’s Laboratories and its subsidiary filed three NDAs for psoriasis, rosacea and migraine
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma™, LLC announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA).
- Read more about India examines WTO option over EU drug suspension order
India is examining whether to take up with World Trade Organisation (WTO) the European Union's (EU) suspension order for sale of about 700 generic drugs which were approved based on clinical trials by pharma major GVK Biosciences.
- Read more about Sun Pharma, Israel university ink pact to develop anti-cancer drugs
Sun Pharmaceutical Industries has inked a pact with Israel's Technion university to develop anti-cancer drugs. The subsidiaries of the Mumbai-based drug firm and Technion - Israel Institute of Technology have entered into an exclusive worldwide research and license agreement, Sun Pharma said in a statement.
- Read more about US FDA approved Aurobindo anesthesia supplement drug product
Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.